Navigation Links
The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecom's Metro Ethernet Service
Date:5/22/2008

ide Surgical facilities, all 12 of The Oregon Clinic's locations are seamlessly connected to one another through Time Warner Telecom's Portland area network. Transmission speeds vary up to 1 Gbps per location. Together, these locations support the clinic's ability to provide more than 120,000 patient appointments annually. Furthermore, The Oregon Clinic's metro Ethernet solution economically provides substantial bandwidth to meet the firm's goal of transmitting electronic medical record (EMR) data as well as patient exam images to physicians on the network as quickly as possible.

The network extension further provides The Oregon Clinic the ability to deploy a real-time, data backup disaster recovery solution. The DR solution will leverage their enterprise disk arrays to back up The Oregon Clinic's 17 terabytes of patient and enterprise data to the firm's data center facility across a Time Warner Telecom 500 Mbps metro Ethernet link. "The Time Warner Telecom, high-capacity circuits will reduce our recovery time from hours to minutes," said McMillian.

"The demand for cost-effective, reliable and secure data circuits from health care facilities and other businesses is driving our program to expand our fiber network to new areas of Portland," said Jon Nicholson, Vice President and General Manager for Time Warner Telecom in Portland. "Our metro Ethernet service easily scales to from 1Gbps and higher to handle our customers' most bandwidth-intensive data transport needs. Together, our national network, 75 metropolitan networks across the country and thousands of buildings on our network, companies can easily share large data files in town or across the country."

Time Warner Telecom is changing its name to tw telecom on July 1, 2008.

About Time Warner Telecom

Time Warner Telecom Inc., headquartered in Littleton, Colo., provides managed network services, specializing in Ethernet and transport data networking, Internet access, local and lon
'/>"/>

SOURCE Time Warner Telecom Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Paramedics, EMTs in Oregon, Washington State Ratify First-Ever Teamsters Contract
2. Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight
3. West Coast Bank Sponsors Reach the Bridge Run to Benefit the American Lung Association of Oregon
4. Oregon Supreme Court Rules in Favor of R.J. Reynolds Tobacco Company in Medical Monitoring Suit
5. Providence St. Vincent bringing IMRISneuro, the worlds most advanced surgical MRI to Portland, Oregon
6. DNA Find in Oregon Is Oldest Yet Discovered in Americas
7. Oregon study raises questions on synthetic progestins
8. Providence Health & Services - Oregon Region Powers Consumer Portal With Kryptiq Connect IQ
9. Oregon researchers discover a mechanism leading to cleft palate
10. Oregon researchers find trigger gene for muscle development
11. TriWest Contributes $30,000 to Oregon National Guard Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Haemonetics Corporation (NYSE: HAE ) announced ... action to stop Fenwal Inc.,s continued patent infringement ... kits, using a modified separation chamber. Fenwal ... patent and the injunction entered by the Court ... December 1, 2010. According to statements made ...
(Date:12/14/2009)... Calif., Dec. 14 Tough Enough To Wear ... breast cancer, celebrated its fifth anniversary at the ... the Wrangler National Finals Rodeo (Wrangler NFR) in ... with rough-and-tumble rodeo cowboys, the support of the ... the sold-out crowd sported pink shirts, hats, bracelets ...
(Date:12/14/2009)... Staff , ... La Jolla, Calif. (Vocus) -- The ... MD, as the new chief of staff of the 372-bed facility. ... team on Jan. 1, 2010. , , , , ,During his ... Scripps La Jolla’s administrative staff and its board of directors. Dr. ...
(Date:12/14/2009)... Critical to Stemming Tide of Tens of Thousands ... WASHINGTON, Dec. 14 Legislation approved by ... will be crucial in helping to reduce tens ... each year in the United States, the ... The provision was included in the FY ...
(Date:12/14/2009)... Dec. 14 When Kurth Krause, an ... instructions for landing on the moon, he,was confident ... anything.,Years later, Kurth realized there was one thing ... kidney transplant and even though dialysis machines,would keep ... a transplant. Kurth,wrote: "My wife is 69 and ...
Breaking Medicine News(10 mins):Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... approved for use as second line therapy for chronic myelogenous ... diagnosed patients in two clinical trials, research teams led by ... Center report at the 49th annual meeting of the American ... trials have a complete cytogenetic response - absence of the ...
... LOS ANGELES, Dec. 9 A federal court ... a harsh spotlight on the pharmaceutical firm,Johnson & ... of,false advertising the controversial chemical sweetener Splenda. United,States ... request for,summary judgment based on that charge that ...
... with high levels of D-dimer face greatest chance of ... Levels of certain blood markers may increase the risk ... relieve symptoms of menopause, new research shows. , ... whether to take the hormone therapy, said the authors ...
... FL, December 8, 2007 A series of studies ... annual meeting elucidates evidence that there is a genetic ... scientific explanation for lower rates of cancer among patients ... rates of smoking and their parents. ...
... arson is a reminder that we must remain vigilant,in ... safety of,the dedicated health care professionals who provide that ... a,statement of Vicki Saporta, President and CEO of the ... Curtis Boyd, MD, in Albuquerque,NM:, As the professional ...
Other Medicine News:Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward 2Health News:Blood Markers Might Predict Clotting Risk With HRT 2Health News:Blood Markers Might Predict Clotting Risk With HRT 3Health News:Studies elucidate genetic links between cancer and schizophrenia 2
(Date:12/14/2009)... 14 In response to an ... in which the Agency recommended that healthcare facilities ... sterile processing system, hospitals throughout the U.S. are ... to that product. According to the FDA, STERIS ... that may affect the safety or the effectiveness ...
(Date:12/14/2009)... -- Following is a statement by Linda A. ... Association (CHPA), regarding today,s release of the National ... survey: ,, "Findings released today on this year,s ... for continued efforts to educate and empower parents ... their teens about medicine abuse. The Consumer Healthcare ...
(Date:12/14/2009)... The board of directors of Eli Lilly ... a dividend for the first quarter of 2010 of ... ,, The dividend is payable March 10, 2010 to ... ,, February 12, 2010. ,, Lilly, a leading ... products by applying the latest research from its own ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 1Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 1Protein handlers should be effective treatment target for cancer and Alzheimers 9501 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 3America Takes on the Challenge to Fight Obesity 53865 1America Takes on the Challenge to Fight Obesity 53865 2America Takes on the Challenge to Fight Obesity 53865 3America Takes on the Challenge to Fight Obesity 53865 4
... lowest dose groups show dose-dependent PSA ... declines to date in all patients - - ... SAN FRANCISCO, Nov. 5 Medivation, Inc.,(Nasdaq: MDVN ) today ... levels of prostate specific,antigen (PSA), a marker of tumor growth, in the ...
... non-responders to previous interferon-based therapy -, - SVR results in ... non- responders, with less frequent dosing -, - ... American Association for the Study of Liver Diseases ... (AASLD) -, ROCKVILLE, Ma., Nov. 5 ...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... This latest sensor array with ... inter-channel spacing of just 2.2 ... is particularly useful when using ... Synthetic Aperture Magnetometry (SAM) or ...
... supine measurement position is achieved using an ... a non-magnetic, mobile patient bed. The patient ... shielded room. In case of an emergency ... the shielded room for e.g. resuscitation purposes. ...
... The Magnes 1300 C is ideal for ... brain and other parts of the body. Often ... its possibilites, including magnetocardiography, gastrointestinal tract, fetal, spinal ... ,The 1300 C, with its 67 detector ...
... one-of-kind portable Digital Radiography system designed for diverse ... a 14 x 17- inch imaging area and ... large imaging area and lightweight design, the CXDI-50G ... Radiography. It is large enough for chest and ...
Medicine Products: